This thesis is based on four projects focused on the Axl receptor tyrosine kinase (RTK) and microRNAs in clear cell renal cell carcinoma (ccRCC) and in prostate cancer (PCa). Paper I focuses on differentially expressed microRNAs in ccRCC. We used bioinformatics methods to identify candidate microRNAs in a publically available cohort of ccRCC, which were measured in a cohort of 198 RCC tumors. Importantly, we identified a 2-microRNA ratio, miR(21/10b), which is an independent prognostic factor in metastasis-free ccRCC patients. These microRNAs are both linked to chronic kidney disease, a risk factor for ccRCC, and could potentially be involved in the progression from kidney disease to renal cancer. In Paper II, our aim was to elucidate if members of the miR-34 family, which is a family of microRNA tumor suppressors, could regulate Axl in ccRCC, and also to determine miR-34a/b/c expression in ccRCC tumors, as reports have been conflicting. Axl has previously been shown to be a target of miR-34a in solid cancers, and high Axl expression correlates with worsened prognosis in RCC. We showed that both miR-34a and miR-34c are direct regulators of Axl in vitro, however miR-34a expression is increased in ccRCC and does not correlate with Axl mRNA or protein in ccRCC tumors, and has no correlation with survival in ccRCC. Paper III was aimed at elucidating whether any of the miR-34 family members could regulate Axl expression PCa, as both miR-34a and miR-34c are downregulated in PCa, and Axl expression is increased in PCa and correlates with disease severity. In addition, we sought to elucidate the role of decreased Axl expression in miR-34a/c-mediated tumor suppression. Although we could show direct regulation of Axl by miR-34a and miR-34c, our results did not support regulation of Axl as the main function in miR-34a/c tumor suppression in PCa. The main functional outcome of miR-34a/c-mediated loss of Axl seemed to be in reduced proliferation in response to Gas6. Finally, paper IV has the aim of investigating the role of Gas6/Axl signaling in Sunitinib treatment in ccRCC. Axl has been linked to resistance to targeted therapies in cancer. Sunitinib is an angiogenesis-inhibiting drug used in treatment of advanced ccRCC, however disease progression eventually occurs in many patients. We show that Sunitinib does not inhibit Axl activation by Gas6; instead Axl phosphorylation was enhanced in the presence of Gas6 and Sunitinib, both in ccRCC cells and in endothelial cells. Moreover, we observed activation of Akt pathway in Sunitinib-treated cells, which was enhanced by the addition of Gas6. In addition Sunitinib activated the epidermal and hepatocyte growth factor receptors, an effect that was augmented by Gas6. Interestingly, Gas6 stimulation was associated with secretion of Osteopontin, associated with tumor angiogenesis, an effect that was increased by Sunitinib.
- Dahlbäck, Björn, handledare
- Axelson, Håkan, handledare
|2015 maj 28
|Published - 2015
Place: Jubileumsaulan, ingång 59, Skånes Universitetssjukhus i Malmö
Name: Allgayer, Heike
Affiliation: Experimental Surgery, Mannheim Medical Faculty, University of Heidelberg